CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
相关临床试验
21
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2013
进行中（未招募）
3
14.3%
已完成
2
9.5%
尚未招募
1
4.8%
招募中
10
47.6%
终止
4
19.1%
Unknown
1
4.8%
暂无批准数据
- The novel hypercholesterolemia drugs market is projected to grow from USD 17.6 billion in 2026 to USD 42.8 billion by 2036, a 9.3% CAGR. - PCSK9 inhibitors are forecast to hold a 42.0% drug-class share in 2026, spanning monoclonal antibodies, inclisiran-based siRNA, and the new oral enlicitide. - Merck's Lipfendra (enlicitide) gained FDA approval in July 2026 as the first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia. - Injectable therapies lead with a 57.0% route-of-administration share, while gene-editing programs from Verve, CRISPR Therapeutics, and Eli Lilly advance toward one-time treatment.
- The T-Cell Lymphoma drug pipeline is advancing with key players like Eisai, Takeda, and Rhizen Pharmaceuticals developing innovative therapies. - Immunomodulatory drugs such as Lenalidomide and monoclonal antibodies like Isatuximab SAR650984 are in clinical trials, showing potential in improving patient outcomes. - Regulatory support, including fast-track designations, is expediting the development and approval of novel T-Cell Lymphoma treatments. - CAR T-cell therapy, such as lisocabtagene maraleucel (Breyanzi), has been approved for certain lymphomas, offering new options for patients who have not responded to other treatments.
